Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Type 1 Diabetes | Research

A comparative study of cardiovascular risk stratification methods in type 1 diabetes mellitus patients

Authors: Fabiano Malard de Araujo, Fábio Vasconcellos Comim, Rodrigo N. Lamounier, Natália F. Pena, Virgínia C. Fajardo, Regina Bicalho G. de Faria, Yuri M. Silva, Márcio Weissheimer Lauria

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

The Steno Diabetes Center Copenhagen developed the Steno T1 Risk Engine (ST1RE) to predict cardiovascular events, encompassing fatal and nonfatal ischemic heart disease, ischemic stroke, heart failure, and peripheral arterial disease in type 1 diabetes mellitus(T1DM).
The current study investigated the agreement between ST1RE and the Brazilian Society for Endocrinology and Metabology (SBEM) classification. Participants were included in the study if diagnosed with T1DM and had at least one outpatient visit in 2021. Patients with established cardiovascular disease and chronic kidney disease on dialysis were excluded. Clinical parameters were obtained from medical records, such as age, body mass index (BMI), blood pressure, physical activity, current smoking, microvascular target organ damage, levels of low-density lipoprotein cholesterol, creatinine, glycated hemoglobin (HbA1c), and albuminuria.
Overall, 92 patients (38 males and 53 females) with an age median (P25; P75) of 33 years (25.5;42.5), BMI of 24.8 + 4.1 kg/m2, and duration of diabetes (mean ± SD) of 23.4 + 9.5 years were evaluated. There were no differences considering the gender for most analyzed variables, but a higher proportion of women exhibited microvascular complications such as microalbuminuria, macroalbuminuria, and retinopathy. Our results show a weak agreement in the 10-year cardiovascular risk estimation between SBEM and ST1RE classifications. According to SBEM criteria, 72.8% of patients were considered high-risk, while only 15.2% of patients received the same classification using ST1RE. The dissimilarities between these two classifications were also evident when age and gender factors were compared. While 60% of patients under 35 years were classified as high risk according to SBEM criteria, only 1.8% received this stratification risk in the ST1RE classification.
The results indicate a low agreement between the 10-year cardiovascular event risk classification by SBEM and the classification by ST1RE for type 1 diabetes patients without established cardiovascular disease.
Literature
1.
go back to reference Livingstone SJ, et al. Risk of Cardiovascular Disease and total mortality in adults with type 1 Diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.CrossRefPubMedPubMedCentral Livingstone SJ, et al. Risk of Cardiovascular Disease and total mortality in adults with type 1 Diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.CrossRefPubMedPubMedCentral
2.
go back to reference Soedamah-Muthu SS, et al. High risk of Cardiovascular Disease in patients with type 1 Diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29(4):798–804.CrossRefPubMed Soedamah-Muthu SS, et al. High risk of Cardiovascular Disease in patients with type 1 Diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29(4):798–804.CrossRefPubMed
3.
go back to reference Secrest AM, et al. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 Diabetes. Diabetes. 2010;59(12):3216–22.CrossRefPubMedPubMedCentral Secrest AM, et al. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 Diabetes. Diabetes. 2010;59(12):3216–22.CrossRefPubMedPubMedCentral
4.
go back to reference Davis TM, et al. U.K. prospective Diabetes study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care. 1997;20(9):1435–41.CrossRefPubMed Davis TM, et al. U.K. prospective Diabetes study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care. 1997;20(9):1435–41.CrossRefPubMed
5.
go back to reference Gerstein HC, et al. Albuminuria and risk of cardiovascular events, death, and Heart Failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.CrossRefPubMed Gerstein HC, et al. Albuminuria and risk of cardiovascular events, death, and Heart Failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.CrossRefPubMed
6.
go back to reference Ninomiya T, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in Diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.CrossRefPubMedPubMedCentral Ninomiya T, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in Diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.CrossRefPubMedPubMedCentral
7.
go back to reference Goff DC Jr., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.PubMed Goff DC Jr., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.PubMed
8.
go back to reference Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol. 2006;17(6):637–43.CrossRefPubMed Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol. 2006;17(6):637–43.CrossRefPubMed
9.
go back to reference Zambanini A, Smith MR, Feher MD. Prediction of cardiovascular risk. Program is not suitable for diabetic patients BMJ, 1999. 318(7195): p. 1418; author reply 1419. Zambanini A, Smith MR, Feher MD. Prediction of cardiovascular risk. Program is not suitable for diabetic patients BMJ, 1999. 318(7195): p. 1418; author reply 1419.
10.
go back to reference Zgibor JC, et al. Deficiencies of cardiovascular risk prediction models for type 1 Diabetes. Diabetes Care. 2006;29(8):1860–5.CrossRefPubMed Zgibor JC, et al. Deficiencies of cardiovascular risk prediction models for type 1 Diabetes. Diabetes Care. 2006;29(8):1860–5.CrossRefPubMed
11.
go back to reference Stevens RJ, et al. The UKPDS risk engine: a model for the risk of coronary Heart Disease in type II Diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6):671–9.CrossRefPubMed Stevens RJ, et al. The UKPDS risk engine: a model for the risk of coronary Heart Disease in type II Diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6):671–9.CrossRefPubMed
12.
go back to reference Juutilainen A, et al. Similarity of the impact of type 1 and type 2 Diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008;31(4):714–9.CrossRefPubMed Juutilainen A, et al. Similarity of the impact of type 1 and type 2 Diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care. 2008;31(4):714–9.CrossRefPubMed
13.
go back to reference Huxley RR, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 Diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(3):198–206.CrossRefPubMed Huxley RR, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 Diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(3):198–206.CrossRefPubMed
14.
go back to reference Vistisen D, et al. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: the Steno type 1 risk engine. Circulation. 2016;133(11):1058–66.CrossRefPubMed Vistisen D, et al. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: the Steno type 1 risk engine. Circulation. 2016;133(11):1058–66.CrossRefPubMed
15.
go back to reference Vinals C et al. Steno type 1 risk engine and preclinical Atherosclerosis in Mediterranean individuals with type 1 Diabetes. Diabetes Metab Res Rev, 2020: p. e3320. Vinals C et al. Steno type 1 risk engine and preclinical Atherosclerosis in Mediterranean individuals with type 1 Diabetes. Diabetes Metab Res Rev, 2020: p. e3320.
16.
go back to reference Llaurado G, et al. Arterial stiffness is highly correlated with the scores obtained from the Steno type 1 risk engine in subjects with T1DM. PLoS ONE. 2019;14(9):e0220206.CrossRefPubMedPubMedCentral Llaurado G, et al. Arterial stiffness is highly correlated with the scores obtained from the Steno type 1 risk engine in subjects with T1DM. PLoS ONE. 2019;14(9):e0220206.CrossRefPubMedPubMedCentral
17.
go back to reference Boscari F, et al. Performance of the Steno type 1 risk engine for Cardiovascular Disease prediction in Italian patients with type 1 Diabetes. Nutr Metab Cardiovasc Dis. 2020;30(10):1813–9.CrossRefPubMed Boscari F, et al. Performance of the Steno type 1 risk engine for Cardiovascular Disease prediction in Italian patients with type 1 Diabetes. Nutr Metab Cardiovasc Dis. 2020;30(10):1813–9.CrossRefPubMed
18.
go back to reference Tecce N, et al. Evaluation of cardiovascular risk in adults with type 1 Diabetes: poor concordance between the 2019 ESC risk classification and 10-year cardiovascular risk prediction according to the Steno type 1 risk engine. Cardiovasc Diabetol. 2020;19(1):166.CrossRefPubMedPubMedCentral Tecce N, et al. Evaluation of cardiovascular risk in adults with type 1 Diabetes: poor concordance between the 2019 ESC risk classification and 10-year cardiovascular risk prediction according to the Steno type 1 risk engine. Cardiovasc Diabetol. 2020;19(1):166.CrossRefPubMedPubMedCentral
19.
go back to reference Cano A et al. Utility of insulin resistance in estimating Cardiovascular risk in subjects with type 1 Diabetes according to the scores of the Steno type 1 risk engine. J Clin Med, 2020. 9(7). Cano A et al. Utility of insulin resistance in estimating Cardiovascular risk in subjects with type 1 Diabetes according to the scores of the Steno type 1 risk engine. J Clin Med, 2020. 9(7).
20.
go back to reference Jensen MT, et al. Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 Diabetes and without known Heart Disease: the Thousand & 1 study. Diabetologia. 2019;62(12):2354–64.CrossRefPubMed Jensen MT, et al. Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 Diabetes and without known Heart Disease: the Thousand & 1 study. Diabetologia. 2019;62(12):2354–64.CrossRefPubMed
21.
go back to reference Bertoluci MC, et al. Brazilian guidelines on prevention of Cardiovascular Disease in patients with Diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr. 2017;9:53.CrossRefPubMedPubMedCentral Bertoluci MC, et al. Brazilian guidelines on prevention of Cardiovascular Disease in patients with Diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr. 2017;9:53.CrossRefPubMedPubMedCentral
23.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed
24.
go back to reference Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and Cardiovascular Disease in men and women with Diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29–36.CrossRefPubMed Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and Cardiovascular Disease in men and women with Diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29–36.CrossRefPubMed
Metadata
Title
A comparative study of cardiovascular risk stratification methods in type 1 diabetes mellitus patients
Authors
Fabiano Malard de Araujo
Fábio Vasconcellos Comim
Rodrigo N. Lamounier
Natália F. Pena
Virgínia C. Fajardo
Regina Bicalho G. de Faria
Yuri M. Silva
Márcio Weissheimer Lauria
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-023-01224-5

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.